SCHEMBL6696149

SCHEMBL6696149

CCOC(=O)CCc1c(C(=O)OCC)[nH]c2c1CCCCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
MAPK1 P28482 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.44
BRD4 O60885 1/20 0.43
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.38
CYP4F2 P78329 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6297621 0.99 LMNA (0.49) LMNAMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL7956193 0.79 LMNA (0.56) LMNAMAPK1MEN1KMT2ANPC1
SCHEMBL7823939 0.78 LMNA (0.57) LMNAMAPK1MEN1KMT2ANPC1
SCHEMBL11276300 0.76 LMNA (0.68) LMNAMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL24375267 0.75 LMNA (0.55) LMNAMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL3344033 0.74 LMNA (0.47) LMNAMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL11650702 0.74 MAPK1 (0.65) LMNAMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL2075491 0.74 LMNA (0.63) LMNASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL7050246 0.72 LMNA (0.51) LMNAMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL11648860 0.71 NPSR1 (0.59) LMNAMAPK1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186160-A1 Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors SUGEN, INC. 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186160-A1 Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors MAP3K15, MAP3K20, MAP3K19 LMNA 4797/4885MAPK1 131/4885SMN1; SMN2 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.